HCC CSCs may provide a novel therapeutic model for the disease.
The recent discovery of cancer stem cells (CSCs) has played a pivotal role in changing our view of carcinogenesis and chemotherapy. Based on this concept, CSCs are responsible for the formation and growth of neoplastic tissue and are naturally resistant to chemotherapy, explaining why traditional chemotherapies can initially shrink a tumor but fails to eradicate it in full, allowing eventual recurrence. Recently, we identified a CSC population in hepatocellular carcinoma (HCC) characterized by their CD133 phenotype. However, the molecular mechanism by which it escapes conventional therapies remains unknown. Here, we examined the sensitivity of these cells to chemotherapeutic agents (doxorubicin and fluorouracil) and the possible mechanistic pathway by which resistance may be regulated. Purified CD133 þ HCC cells isolated from human HCC cell line and xenograft mouse models survived chemotherapy in increased proportions relative to most tumor cells which lack the CD133 phenotype; the underlying mechanism of which required the preferential expression of survival proteins involved in the Akt/PKB and Bcl-2 pathway. Treatment of CD133 þ HCC cells with an AKT1 inhibitor, specific to the Akt/PKB pathway, significantly reduced the expression of the survival proteins that was normally expressed endogenously. In addition, treatment of unsorted HCC cells with both anticancer drugs in vitro significantly enriched the CD133 þ subpopulation. In conclusion, our results show that CD133 þ HCC cells contribute to chemoresistance through preferential activation of Akt/PKB and Bcl-2 cell survival response. Targeting of this specific survival signaling pathway in CD133 þ Introduction Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide affecting one million individuals annually (Thorgeirsson and Grisham, 2002) . Liver resection or transplantation is available for early-stage HCC; however, most patients with the disease are usually diagnosed at an advanced stage, resulting in the limited efficacy of these potentially curative therapies. Further, the fact that HCC is resistant to conventional chemotherapy or radiotherapy leaves this disease with no effective therapeutic options and a very poor prognosis.
The 'stem cell model' of carcinogenesis suggests that cancers originate and are maintained by a rare fraction of cells called cancer stem cells (CSCs) (Reya et al., 2001; Pardal et al., 2003) . These cells not only possess unique survival mechanisms but also harbor distinctive stem/progenitor cell properties including the ability to self-renew, differentiate and proliferate following a prolonged period of quiescence. If tumor growth and metastasis are really driven by CSCs, this can explain why current chemotherapies, developed largely against the bulk tumor mass, are only transiently, if at all, able to shrink the primary tumor, but are unable to provide a lasting cure for the disease. It is likely that these residual CSCs, due to their resistance ability, are able to survive in a dormant state for many years after remission and result in tumor relapse, with renewed resilience and aggression.
To date, the existence of CSCs has been proven in the context of many cancers, including those of leukemia, breast cancer, glioblastoma, prostate cancer, pancreatic cancer and colon cancer (Lapidot et al., 1994; Bonnet and Dick, 1997; Al-Hajj et al., 2003; Hemmati et al., 2003; Singh et al., 2003 Singh et al., , 2004 Collins et al., 2005; Ponti et al., 2005; Haraguchi et al., 2006; Patrawala et al., 2006; Li et al., 2007; O'Brien et al., 2007; Ricci-Vitiani et al., 2007) . Recently, we have determined that HCC is hierarchically organized and originates from a primitive stem/progenitor group of cells for which CD133 þ precursors constitute one of the most immature stage (Ma et al., 2007) . CD133 þ HCC cells isolated from human HCC cell lines and xenograft tumors not only possess a greater colony-forming efficiency, higher proliferative output and greater ability to form tumor in vivo but are also endowed with characteristics similar to those of stem/progenitor cells including the preferential expression of 'stemness' genes, the ability to selfrenew and the ability to differentiate. Further, CD133 represents only a minority of the tumor cell population in human HCC specimens (Suetsugu et al., 2006; Ma et al., 2007; Yin et al., 2007) .
To date, CD133 has also been shown to mark the CSC population in cancers of the brain, prostate, pancreas and colon (Hemmati et al., 2003; Singh et al., 2003; Li et al., 2007; O'Brien et al., 2007; Ricci-Vitiani et al., 2007) . Preliminary studies have attributed the high expression levels of specific ABC drug transporters to the increased resistance of CD133 CSCs to chemotherapeutic agents (Dean et al., 2005; Haraguchi et al., 2006) . Yet despite extensive research efforts, the specific signaling pathway and mechanism of action to how CD133 CSCs are able to evade conventional therapies, in HCC or other cancer types, remains largely unknown.
In this study, we evaluated the chemosensitivity and susceptibility as cytotoxic targets of CD133 þ HCC stem/progenitor cells, extracted from HCC cell lines and xenograft tumors, to two anticancer drugs commonly used in the treatment of HCC-doxorubicin (DOX) and fluorouracil (5-FU). We then examined the possible mechanistic pathway for chemoresistance conferred by the preferential expression of CD133. Here, we demonstrate for the first time that the recently identified CD133 þ HCC CSCs represent the cellular population that confers chemoresistance and could be the source of tumor recurrence after chemotherapy. CD133
þ HCC cells survive chemotherapy in increased proportions relative to most tumor cells, which lack the CD133 phenotype; the underlying mechanism of which required the sustained activation of the Akt/PKB and Bcl-2 cell survival pathways. The expression of survival proteins including active phosphoserine-specific Akt (473), inactive phosphoserine-specific Bad (136) and Bcl-2 in CD133 þ HCC cells, persisted for a significantly longer period of time and also when exposed to higher concentrations of both drugs, than when compared to unsorted cells or its corresponding CD133
À counterparts. Further, CD133 was found to be co-expressed with active Akt (phosphorylated at Ser473) and Bcl-2. Treatment of CD133 þ HCC cells with an inhibitor specific to AKT1 particularly reduced the expression of these cell survival proteins that was normally expressed endogenously. In addition, treatment of unsorted cells with both chemotherapeutic agents in culture specifically targeted tumor cells lacking CD133 phenotype, thus resulting in the marked increase of the CD133 þ subpopulation. Overall, the finding that CD133 HCC CSCs can trigger a distinct anti-apoptotic cell survival pathway leading to chemotherapeutic resistance may have pivotal biological implications for a better understanding of both drug resistance in tumors, as well as the selective advantages conferred to cells expressing this receptor.
Results and discussion

CD133
þ HCC cells confer chemoresistance to conventional chemotherapeutic agents We hypothesized that CD133
þ HCC cells, which we have recently shown to represent the exclusive population of CSCs in HCC, would demonstrate resistance to traditional chemotherapeutic agents (Dean et al., 2005; Haraguchi et al., 2006) . Both cell proliferation and apoptosis binding assays were used to examine the sensitivity of sorted CD133 þ and CD133 À cells from both human HCC cell line PLC8024 (Figure 1 , expressed CD133 in 60% of the cells) and short-term culture of cells derived from CD133
þ (Huh7 human cell line)-induced xenograft tumor (Ma et al., 2007) (data not shown, expressed CD133 in 65% of the cells).
Sorted CD133 þ and CD133 À HCC cells were exposed for 72 h to varying concentrations of DOX (0, 1, 2.5 and 5 mg ml
À1
; IC 50 at 2.5 and 1.5 mg ml À1 for CD133 þ -induced xenograft tumor and PLC8024, respectively) and fluorouracil (5-FU; 0, 5, 10, 25 and 75 mg ml À1 ; IC 50 at 10 and 75 mg ml À1 for CD133 þ -induced xenograft tumor and PLC8024, respectively), chemotherapeutic agents commonly used in the treatment of HCC. Figure 2d ) are incorporated to eliminate the possibility that the inhibitory effects of the two drugs are influenced by the growth ability of the two populations. Note that following cell sorting, cells were immediately plated and cultured for several hours until cell attachment followed by the addition of the two drugs. Cells would be harvested 72 h later at which time cell viability will be measured by the XTT cell proliferation assay. As evident in the graphs, the growth of CD133 þ and CD133 À cells are more or less similar before day 3, which was the time needed to conduct the XTT cell proliferation experiments. It is only around day 5 does the proliferation of the two subpopulations begin to differ drastically. The preferential survival of CD133 þ HCC cells after therapy was due to lower rates of apoptosis, as indicated by Annexin V/PI apoptosis staining (Figures 3a-d þ subpopulation in vitro, whereas CD133 expression in the untreated cells remained relatively unchanged, providing direct evidence supporting our hypothesis that chemotherapeutic agents are only able to eradicate the bulk of the tumor cells but not the CSCs (Table 1) .
CD133
þ HCC cells confer chemoresistance via the preferential activation of the Akt/PKB and Bcl-2 survival pathway The evasion of programmed cell death is now recognized as one of the six essential alterations in cell physiology that dictate malignant growth and has been proven to be a hallmark of most, if not all, types of cancer (Hanahan and Weinberg, 2000; Fesik, 2005) . Most currently available cytotoxic drugs induce tumor death by triggering apoptosis, but many tumors have defects in the regulation of genes that control this process, thus rendering them resistant to chemotherapeutic agents. The serine/threonine kinases MAPKs (mitogen-activated protein kinases) and Akt/PKB (protein kinase B) are well-recognized mediators of cell survival in response to a number of stimuli (Nicholson and Anderson, 2002; Vivanco and Sawyers, 2002 ; Sebolt-Leopold and þ (Huh7)-induced xenograft tumor and (e and f) PLC8024 HCC cell line show increased resistance to chemotherapeutic agents. Cells were maintained in complete medium for several hours until cell attachment at which time chemotherapeutic agents 5-FU and DOX were added, at various concentrations ranging from 0 to 75 and 0 to 5 mg ml À1 , respectively, and allowed to incubate for an additional 72 h. Cell viability was determined by XTT cell proliferation assay (black bar, CD133 þ cells; white bar, CD133 À cells). Data represent the mean7s.d. derived from two independent experiments with triplicate wells per condition.
þ , 2004) , and have been implicated to play a pivotal role in cytotoxic drugs-mediated apoptosis in HCC (Fabregat et al., 2007) . Specifically, the Akt/PKB pathway and members of the Bcl-2 survival family have been studied extensively and shown to play an important anti-apoptotic role in many cancers (Nicholson and Anderson, 2002; Sebolt-Leopold and Herrera, 2004) . Several mechanisms have been described for how Akt/ PKB suppresses apoptosis. One involves the phosphorylation of caspase-9, one of the 'executioner' caspases in the apoptotic cascade, thereby suppressing its function. Another is dependent on glycogen synthase kinase-3, another substrate of Akt. The alteration of Bcl-2 protein expression via phosphorylation of the pro-apoptotic members of its Bcl-2 protein family, Bad, has also been identified as a key target of Akt cell survival-signaling pathway (Datta et al., 1997; Adams and Cory, 1998) .
In order to address the mechanism by which CD133 À counterparts, display a marked preferential expression of survival proteins involved in the Akt/PKB and Bcl-2 pathway, including active Akt (phosphorylated at Ser473), inactive Bad (phosphorylated at Ser136) and Bcl-2, providing evidence suggesting that CD133 is at least partly, if not fully, able to confer resistance via this pathway (Figure 4 ). Elevated expression of both phosphoserine-specific Akt and Bad in CD133 þ HCC cells was not a result of an increase in total Akt or total Bad protein levels. No difference was observed between the expressions of the MEK/ERK signaling cascade proteins in CD133 þ and CD133 À cells (Figure 4 ). b-actin was used as a control for equal loading and CD133 was used to ensure that post-sorted CD133 þ and CD133 À subpopulations were pure following cell sorting by flow cytometry.
To study whether the Akt/PKB and Bcl-2 pathway played a role in the CD133 þ -mediated resistance to DOX and 5-FU in HCC cells, we examined the expression of the Akt/PKB pathway-related proteins in both PLC8024 HCC cell line and short-term culture of cells derived from CD133 þ (Huh7)-induced xenograft tumor after treatment with both DOX and 5-FU. Unsorted, CD133 þ or CD133 À cells were incubated for either 72 h with different concentrations of DOX varying from 0 to 5 mg ml À1 or 5-FU varying from 0 to 150 mg ml À1 (Figures 5a-d) or with a constant 5 mg ml
À1
of DOX or 25 mg ml À1 of 5-FU for varying time points ranging from 0 to 72 h (Figures 5e-h) . Whole cell lysates were subjected to western blot analysis for expression of CD133, phosphorylated and total Akt, phosphorylated Bad and Bcl-2. Unsorted cells display both a time-and concentration-dependent decrease in CD133, active Akt, inactive Bad and Bcl-2, with its expression significantly downregulated when exposed to 5 mg ml À1 of DOX or 75 mg ml À1 of 5-FU for 72 h. The decrease in active Akt was independent of the expression levels of total Akt. The expression of the survival proteins in CD133 þ cells persisted for a longer period of time and when exposed to higher concentrations of both drugs, than when compared to unsorted cells or its corresponding CD133 À counterparts, although expression of CD133 in the CD133 þ subpopulation also eventually diminished when exposed to significantly higher concentrations of drugs and longer periods of time. CD133 À cells expressed little, if at all, any of these survival proteins. Similar results were also obtained from unsorted and sorted cells isolated from PLC8024 HCC cell line (data not shown). As phosphorylation of Akt and Bad is an indication of activation of these proteins, these results suggest that increased CD133 expression is associated with activation of the Akt/PKB and Bcl-2 pathway in response to DOX and 5-FU treatment.
In addition, dual-color immunofluorescence experiments were also conducted to investigate the localization of CD133 and survival proteins active Akt (phosphorylated at Ser473) and Bcl-2 in unsorted PLC8024 HCC cell line and CD133 þ (Huh7)-induced xenograft tumor. PLC8024 HCC cells that expressed CD133 were also found to express and colocalize with phosphoserinespecific Akt and Bcl-2 (Figure 6 ). In contrast, those cells that lacked CD133 phenotype did not express either of these survival proteins. Similar results were also obtained from cells isolated from CD133 þ (Huh7)-induced xenograft tumor (data not shown). Note that the immunofluorescence images in Figure 6 were taken at high magnification and care was taken to select an area where the staining was most clear and precise but unfortunately may not best represent the overall CD133 expression in the PLC8024 HCC cells.
Inactivation of Akt/PKB pathway by an AKT1 inhibitor abolishes the preferential survival of CD133
þ HCC cells via the Akt/PKB and Bcl-2 pathway To further confirm the importance of the Akt/PKB pathway to the increased survival of CD133
þ HCC cells, we assessed the ability of an Akt inhibitor to prevent CD133 þ cell chemoresistance. AKT1 inhibitor, which had been shown to inactivate PKB specifically by reducing phosphorylation, was used to evaluate whether inactivation of Akt/PKB pathway had any effect on cellular sensitivity to DOX and 5-FU. Treatment of CD133 þ and CD133 À HCC cells with the AKT1 inhibitor alone at 10 mM (IC 50 ¼ 10 mg ml À1 for CD133 þ -induced xenograft tumor; IC 50 ¼ 12 mg ml À1 for PLC8024) significantly reduced the expression of the Akt/PKB pathway-related cell survival proteins that was normally expressed endogenously (Figure 7a) .
Further, treatment of CD133 þ and CD133 À HCC cells with the AKT1 inhibitor impacted the proliferation of both subpopulations of cells in a similar effect as does DOX at 1 mg ml À1 or 5-FU at 5 mg ml À1, where all three reagents similarly showed less effect on the CD133 þ than as compared to their CD133 À counterparts. Interestingly, co-incubation of the AKT1 inhibitor with DOX or 5-FU almost completely inhibited the preferential survival effect induced by CD133 þ cells (Figure 7b ). The fact that chemoresistance conferred by CD133 þ HCC CSCs can be reversed with a specific inhibitor to AKT1 provides additional evidence supporting the role of this particular pathway in the increased survival of CD133 þ HCC cells.
Concluding remarks
The recent discovery of CSCs in solid tumors has played a pivotal role in changing our view of carcinogenesis and Figure 4 Western blot analysis for endogenous expression of proteins involved in the MEK/ERK (MAPKs) or Akt/PKB and Bcl-2 cell survival pathways. CD133 þ HCC cells isolated from short-term culture of cells derived from CD133 þ (Huh7)-induced xenograft tumor show significantly elevated levels of active Akt (phosphorylated at Ser473), inactive Bad (phosphorylated at Ser136) and Bcl-2 as compared to its corresponding CD133 À counterparts. Elevated expression of both phosphoserine-specific Akt and Bad in CD133 þ HCC cells was not a result of an increase in total Akt or total Bad protein levels. b-actin was used as a control for equal loading and CD133 was used to ensure that post-sorted CD133 þ and CD133 À subpopulations were pure following cell sorting by flow cytometry. Similar results were also obtained for PLC8024 HCC cell line (data not shown).
CD133
þ
There is an increasing belief and evidence in support of the theory that CSCs may be responsible for the initiation and maintenance of neoplastic tissue. Based on this concept, CSCs are naturally resistant to chemotherapy through their quiescence, their capacity for active DNA repair and ability to evade apoptosis. As a result, these CSCs can survive chemotherapy and support regrowth of the tumor, which explains why traditional therapies can initially shrink, if at all, a tumor but is unable to completely eradicate it, allowing eventual recurrence (Reya et al., 2001; Pardal et al., 2003; Dean et al., 2005 À as compared to a cell line that only expresses only 1-2% CD133 þ cells. But instead of using the pure Huh7 cell line, the authors chose to work with CD133 þ (Huh7)-induced xenograft tumor as there are recent reports suggesting that the basic profile and percentage of tumor-initiating cells isolated from xenograft implants are very similar to those in the primary tumors. Thus in view of this, we chose to work with the PLC8024 cell line and also short-term culture of CD133 þ (Huh7)-induced xenograft tumor, in attempt to provide a more overall Figure 5 Unsorted CD133 þ or CD133 À HCC cells isolated from short-term culture of cells derived from CD133 þ (Huh7)-induced xenograft tumor were either incubated for 72 h with different concentrations of DOX varying from 0 to 5 mg ml À1 (a and b) or with different concentrations of 5-FU varying from 0 to 150 mg ml À1 (c and d), or for varying time points ranging from 0 to 72 h with a constant 5 mg ml À1 of DOX (e and f) or with a constant 25 mg ml À1 of 5-FU (g and h). Whole cell lysates were subjected to western blot analysis for expression of phosphorylated and total Akt, phosphorylated Bad and Bcl-2. Representative blots from two independent experiments are shown. b-actin was used as a control for equal loading and CD133 was used to ensure that post-sorted CD133 þ and CD133 À subpopulations were pure following cell sorting by flow cytometry. Unsorted cells display both a concentration-and timedependent decrease in active Akt, inactive Bad and Bcl-2, with its expression significantly downregulated at 5 mg ml À1 of DOX, 75 mg ml À1 of 5-FU or at a fixed DOX or 5-FU concentration at 72 h time point. The decrease in active Akt was independent of the expression levels of total Akt. The expression of each of these survival proteins in CD133 þ cells persisted at higher concentrations of DOX and 5-FU and also for a longer period of time when exposed to a fixed concentration of DOX or 5-FU, than compared to unsorted cells or its corresponding CD133 À counterparts. CD133 À cells expressed little, if at all, any of these survival proteins. Similar results were also obtained for PLC8024 HCC cell line (data not shown). þ cells were found to co-express with active phosphoserine-specific Akt and Bcl-2; whereas those cells that lacked the CD133 phenotype did not express either of the two proteins. Nuclei (blue) are labeled with DAPI staining. Similar results were also obtained for short-term culture of cells derived from CD133 þ (Huh7)-induced xenograft tumor (data not shown).
þ HCC cancer stem cells confer chemoresistance S Ma et al outlook and increase the relevance of this approach as a model for primary HCC. Furthermore, it is worthwhile to mention that our group previously demonstrated that when these cells were injected into nude or SCID animals, CD133 þ cells were only maintained at a very low frequency in contrast to their in vitro culture environment (Ma et al., 2007) . And in addition to our recent findings, there is also another research group that provided evidence in support of the existence of CD133 þ cells in cancer patient specimens (Yin et al., 2007) . Results show that CD133 þ fraction in human HCC specimens and xenografts ranged from 1 to 3%. Since the percentage of CD133 þ cells in xenograft tumors are very similar to those of human HCC specimens, the authors believe that the chosen models used in this study are relevant in a human primary HCC setting. Several mechanisms have been described for how Akt/PKB suppresses apoptosis, of which includes the alteration of Bcl-2 protein expression via phosphorylation of pro-apoptotic members of its Bcl-2 protein family, Bad. Specifically, phosphorylated Akt at site serine 473 is able to confer survival signals via phosphorylation of Bad at serine 136. Phosphorylated Bad binds to 14-3-3, resulting in it being sequestered in the cytoplasm, and losing the ability to heterodimerize with survival proteins Bcl-xL and Bcl-2, thus resulting an accumulation of these pro-survival/anti-apoptotic signals in the cell. Data presented in this study demonstrate that CD133 þ HCC CSCs contribute to HCC chemoresistance through preferential activation of this specific Akt/PKB and Bcl-2 survival pathway. Therapies targeted at this definite pathway may provide a novel method to sensitize HCC to chemotherapy, and to disrupt the resistance mechanism to improve overall tumor control and reduce HCC tumor recurrence.
Materials and methods
Reagents AKT1 inhibitor (1L6-hydroxymethyl-chiro-inositol-2-(R)-2-Omethyl-3-O-octadecyl-sn-glycerocarbonate) was purchased from Calbiochem (San Diego, CA, USA) (Cat No 124005).
Cell culture Huh7 was provided by Dr H Nakabayashi, Hokkaido University School of Medicine, Japan (Nakabayashi et al., 1982) . PLC8024 was obtained from the Institute of Virology, Chinese Academy of Medical Sciences, Beijing, China.
Xenograft tumor development
The study protocol was approved by and performed in accordance with the Committee of the Use of Live Animals in Teaching and Research at the University of Hong Kong. A total of 5 Â 10 4 CD133 þ cells isolated from Huh7 human HCC cell line were injected subcutaneously into nude mice, as previously described (Ma et al., 2007) .
Xenograft tumor processing
Xenograft tumors formed by subcutaneous injection of CD133 þ cells isolated from Huh7 HCC cell line into nude mice, were processed as previously described (Ma et al., 2007) .
Flow cytometry and cell sorting Cells were incubated in PBS containing 2% FBS with PEconjugated anti-human CD133/1 antibody (Miltenyi Biotec, Aubum, CA, USA). Isotype-matched mouse immunoglobulins 
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